Incyte (NASDAQ:INCY) reported better-than-expected second-quarter earnings and revenue on Tuesday, although its shares edged lower in pre-market trading after the company issued full-year sales guidan
Incyte beat Q2 estimates but slashed full-year guidance and raised expenses on a $1.27B acquisition, sending shares down 31% pre-market.
Incyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $1.67 billion. On the other hand, t
WILMINGTON, Del., July 28, 2026--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.
INCY stock shows a perfect technical breakout setup with a 10/10 Technical Rating and 9/10 Setup Quality, featuring a bull flag pattern and strong momentum.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.
View interactive chart, options flow, and AI analysis for INCY on Zorveq Finance.
Open INCY Chart & Analysis →